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The pressor and antidiuretic actions of arginine vasopressin (AVP) have been well
documented. This review focuses on the less widely appreciated actions of AVP which
also have important physiologic functions and when better understood may provide impor-
tant insights into common disease states.These actions include effects on pain perception
and bone structure as well as important relationships to the varied components of meta-
bolic syndrome. These include effects on blood glucose, lipid levels, and blood pressure.
AVP may also play a role in the progression of chronic kidney disease and effect physio-
logic changes relating to aging, abnormal social behavior, and cognitive function. Important
cellular responses including cell proliferation, inflammation, and control of infection and
their relationship to AVP are described. Finally, the effects of AVP on hemostasis and
the hypothalamic–pituitary–adrenal axis are noted. The goal of this summary of the var-
ious actions of AVP is to direct attention to the potential benefits of research in these
underemphasized areas of importance.
Keywords: arginine vasopressin, metabolic syndrome, social behavior, osteopenia, cell proliferation, hypertension,
chronic kidney disease, inflammation
INTRODUCTION
Arginine vasopressin (AVP), also known as antidiuretic hormone,
is a small peptide with only nine amino acids. It closely resembles
oxytocin differing from it by only two amino acids.
The main site of AVP production is the hypothalamus. Smaller
amounts are also produced outside the hypothalamus in many tis-
sues locally. Thus, apart from its endocrine effect, AVP also exerts
autocrine and paracrine effects. The tracts from the hypothalamus
containing AVP terminate in the posterior pituitary, also called the
neurohypophysis, where AVP is stored. These tracts also innervate
other areas of brain and the spinal cord enabling AVP to exert
its actions not only systemically but locally in the brain and spinal
cord. The most sensitive stimulus for the secretion of vasopressin is
serum osmolality. Although the secretion of AVP is also affected by
changes in blood volume and blood pressure (BP), these responses
require larger variations than changes in serum osmolality (1).
Vasopressin, being a small peptide, is easily filtered through the
glomerulus. It is not metabolized in the kidney being excreted
unchanged in the urine. Under normal physiological conditions,
the concentration of AVP in the plasma is very low (<2 pg/mL)
making it difficult to measure. Copeptin is a surrogate marker
of vasopressin secretion. Copeptin is a peptide which is secreted
along with AVP in equimolar amounts and is easier to monitor as
its half-life is longer and it is more stable (2).
Arginine vasopressin acts primarily through its receptors which
are located in the brain as well as in the periphery. These receptors
are named V1a, V1b, and V2 (Table 1). V1a receptors are present
in many tissues including the smooth muscle cells of vessels, as
well as the brain, adrenal cortex, adipose tissue, and hepatocytes.
V1b receptors are mainly present in anterior pituitary, adrenal
medulla, islet cells of Langerhans, and white adipose tissue. V2
receptors are present in the kidney on the basolateral membrane
of the collecting duct and alveolar epithelial cells (3).
In addition to the well known effects on BP and the kidney,
AVP has also been demonstrated to have numerous other signifi-
cant actions centrally and in the periphery due to its effects on the
various V1a and V1b receptors. It is these varied and important
actions that will be the focus of this comprehensive review and
which are illustrated on Figure 1.
AVP AND PAIN
Arginine vasopressin has a significant effect on pain perception
via the central nervous system through receptors V1a and V1b
located on neuronal cells including those distributed throughout
the hypothalamus. In the brain, these neurons extend to the lat-
eral septum, hippocampus, amygdala, and other brain structures.
Studies have shown that AVP can increase the pain threshold to
painful stimuli (4).
It has been demonstrated that in response to stress and pain,
central as well as peripheral levels of AVP are increased. It is
thought, however, that the analgesic actions of AVP are not medi-
ated by peripheral AVP as the blood–brain barrier (BBB) prevents
the passage of AVP from the periphery to the brain. For exam-
ple, peripheral injection of AVP in rats did not reduce the pain
threshold when rats were given pain in a graded manner (4). In
contrast, further experiments showed that pain perception can
be altered by AVP. Pain was induced in a graded manner by
using techniques like hot plate and tail flick methods. The ini-
tial threshold at which pain occurred was noted. AVP was then
given by an intraventricular route and the pain stimulus was
reapplied. The pain threshold was now significantly higher (4).
In another experiment, a pain stimulus was applied to Brattleboro
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Table 1 | Arginine vasopressin receptors and their locations.
V1a receptors V1b receptors V2 receptors
Smooth muscle cells Anterior pituitary Basolateral membrane
of collecting ducts
Brain Adrenal medulla Alveolar epithelial cells
Adrenal cortex Islet cells of Langerhans Osteoblasts
























FIGURE 1 |The varied nonpressor and nonantidiuretic actions of
vasopressin are illustrated.
rats which are deficient in vasopressin. These rats showed an exag-
gerated pain response. When AVP was given intraventricularly,
the pain threshold increased indicating that the analgesic deficit
was AVP-dependent. Furthermore, the intracerebral action of AVP
was blocked by injecting antiserum against AVP into the ventricle
resulting in a decreased threshold to painful stimuli (5).
In another study, Ahn et al. showed in his animal experiments
that the analgesic actions of AVP were blocked by a V1a and not a
V2 receptor antagonist, suggesting that AVP exerts its antinocicep-
tive activity exclusively through V1a receptors (6). Watkins et al.
showed that not only intracranial but intrathecal injections of
AVP can cause an antinociceptive effect which suggests that the
antinociception action of AVP extends to the spinal cord (7). Yang
et al. demonstrated that, in acute headaches, intranasal AVP was
effective in reducing pain. Intranasal AVP can be effective since
there is a pathway connecting the olfactory neuroepithelium and
brain which enables AVP to bypass the BBB (8). In summary,
multiple studies have confirmed the analgesic actions of AVP.
AVP AND BONE
Pituitary hormones including AVP have a significant effect on
bone. Direct control is exerted through vasopressin and oxytocin.
Indirect control is exerted by thyroxine, gonadal hormones, and
adrenal hormones. These latter hormones are in turn controlled
by pituitary hormones. Oxytocin exerts significant osteoblastic
activity by acting directly on the bone. Mutation of the oxy-
tocin receptor on osteoblasts can cause significant osteopenia.
Oxytocin and AVP are also produced locally in tissues and it is
likely that locally produced pituitary hormones may take part
in skeletal stability. AVP is a key regulator of bone remodeling
by controlling both osteoblast and osteoclast activity through
its receptors. Osteoblasts and osteoclasts both have AVP recep-
tors V1a and V2, and their activation can cause stimulation of
kinases. The latter have been shown to favor stimulation of osteo-
clasts causing bone resorption and osteoporosis while inhibiting
bone formation by osteoblasts. Conversely, antagonists to either
V1a or V2 receptors favor osteoblasts and new bone synthesis
while inhibiting osteoclasts by mechanisms as yet not completely
understood (9).
Furthermore, approximately 50% of chronic hyponatremic
syndromes result from the syndrome of inappropriate antidiuretic
hormone secretion (SIADH). One-third of body sodium is stored
in the bones. Thus, in chronic hyponatremia due to SIADH with
excess AVP activity, there may be bone resorption by osteoclasts
and also by the release of sodium from the bone (10).
In addition, experiments by Barsony et al. demonstrated that
hyponatremia causes direct stimulation of osteoclastogenesis and
osteoclast resorption in young rats. Experiments revealed that low
sodium in the medium directly stimulated osteoclast progeni-
tor cells to produce osteoclasts. They also found that this effect
was not due to hypoosmolality but was due specifically to the
hyponatremia. They exposed the murine preosteoclastic cells to
low sodium in the medium but maintained the osmolality at
normal levels by adding mannitol. In this situation, the conver-
sion of preosteoclastic cells to osteoclasts persisted. In fact, it was
shown that hypoosmolality was protective of bone as low osmolal-
ity induced stretching of cells and increased intracellular calcium
which causes apoptosis of the osteoclasts. Thus, the hyponatremia
was responsible for the increased osteoclastogenesis and increased
osteoclast activation. Increased osteoclastogenesis was seen even
with mild hyponatremia (11).
It also appears that hyponatremia can enhance osteoclast pro-
liferation by inducing oxidative stress. Vitamin C is considered to
be a strong defense against reactive oxygen species. Entry of vit-
amin C into the cell is sodium-dependent and is mediated by a
sodium-dependent ascorbic acid transporter. This transporter is
modulated by extracellular sodium and it has been shown that
even a small reduction in extracellular sodium causes a marked
decline of the uptake of radiolabeled vitamin C. At the same time,
it was shown that the accumulation of reactive oxygen radicals was
increased as a result of reduced intracellular vitamin C and was
directly proportional to the level of hyponatremia. Also, evidence
of oxidative DNA damage was found (11).
Other studies have described an association between endurance
exercise and athlete-related osteopenia. Endurance athletes are
prone to exercise-associated hyponatremia in part related to the
high rate of hypotonic fluid intake during and after exercise. Per-
sistent secretion of AVP contributes to the hyponatremia. Since
bone is thought to buffer significant changes in plasma sodium,
Butler et al. studied this association in endurance athletes. Results
showed that endurance athletes had both pre- and post-race
plasma sodium levels in the normal range although post-exercise
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sodium was lower than pre-exercise sodium. The change in sodium
level pre- and post-exercise was directly related to the change in
bone mineral content. AVP could be related to osteopenia directly
through its action on osteoclasts and indirectly by hyponatremia
causing the release of sodium from bone (12).
Finally, it has been observed that patients with chronic hypona-
tremia have an increased incidence of osteoporosis and there is an
association of hyponatremia with falls and fractures in elderly
patients. A recent study revealed that 9.1% of patients seen in an
emergency setting for fracture were hyponatremic (13).
AVP AND METABOLIC SYNDROME
The metabolic syndrome (MetS) is a complex disorder and is
defined by interconnected factors which include hypertension,
obesity, insulin resistance, pro-inflammatory and pro-thrombotic
state, dyslipidemia, including elevated triglycerides (TGs) and
apolipoprotein B-containing lipoproteins, and low high-density
lipoproteins, non-alcoholic fatty liver disease, and sleep apnea.
MetS increases the risk of diabetes mellitus (DM) and coro-
nary artery disease (CAD). Traditional risk factors for MetS are
well known but it is still debated if this is a distinct syndrome
or a marker of multiple risk factors which places an individual
at high risk for DM and CAD. Biomarkers of MetS are insulin
resistance, leptin, and changes in epinephrine and norepineph-
rine, oxidized low-density lipoprotein cholesterol, uric acid, C-
reactive protein (CRP), plasminogen activator inhibitor-1, and
aldosterone (14). The pathophysiology of MetS is poorly under-
stood. It is observed that even with similar risk factors, age of
onset of MetS varies. This suggests that genetic and environmen-
tal factors play an important role. It is also increasingly recog-
nized that psychosocial stress and dysregulation of hypothalamo–
pituitary axis and autonomic nervous system may play a vital
role (15).
Arginine vasopressin has diverse actions which include vaso-
constriction, platelet aggregation, stimulation of glycogenolysis
from liver, effects on lipids, regulation of ACTH secretion from
the pituitary, and release of insulin and glucagon from the pan-
creas. Thus, AVP may play a role in the development of MetS (14).
It has been postulated that psychosocial stress may be an etiologic
factor in MetS. Normally, corticotropin-releasing hormone (CRH)
and AVP act on the pituitary to release ACTH. However, psychoso-
cial stress amplifies the action of AVP on the pituitary through V1b
receptors to release ACTH. This increase in ACTH causes increased
stimulation of the adrenal cortex and results in high serum cortisol
levels. Mice that lack V1b receptors have a lower level of serum cor-
tisol at stress and at basal state. High serum cortisol causes obesity,
hyperglycemia, and insulin resistance. Moreover, ACTH released
due to AVP stimulation does not respond to negative feedback by
serum cortisol in contrast to CRH-induced ACTH release which
does respond to cortisol levels. AVP has also been shown to directly
simulate the synthesis and release of cortisol throughV1a receptors
in the adrenal cortex (15, 16).
It is difficult to measure AVP as its half-life is only 24 min and
it is rapidly cleared from plasma and also it is attached to platelets.
Copeptin is a surrogate marker of AVP and its level correlates to
levels of AVP in plasma. It is easy to measure copeptin as it is quite
stable, has a long half-life, and is not attached to platelets. Saleem
et al. reported elevated copeptin levels in association with MetS.
Moreover, those who had the highest copeptin levels, in the third
or fourth quartiles for plasma copeptin, had 70–100% higher odds
of MetS compared with those in the bottom quartile. Individuals
with the highest number of MetS components had higher copeptin
levels. Plasma copeptin was also associated with higher TG levels
and lower HDL cholesterol levels and inversely associated with
physical activity (14).
In a study done by Enhorning et al. in Sweden between 1991
and 1994, 2064 patients were serially followed for 15.8 years. Base-
line copeptin levels were measured. At the end of 15.8 years, an
oral glucose tolerance test and measurement of MetS individual
components were done in these subjects. They found that copeptin
levels at baseline could predict the development of abdominal obe-
sity and incident DM. Baseline copeptin levels could also predict
the future incidence of diabetes even without impaired fasting
blood glucose. Thus, copeptin could be used as a screening tool to
detect high-risk individuals who could develop DM in the future
even though they had a normal baseline fasting glucose levels.
They also found that the association between baseline copeptin
and diabetes was independent of the development of obesity.
Further, copeptin levels at baseline were associated with microal-
buminuria after long-term follow-up and this was independent
of baseline MetS variables. This finding may be mediated by the
action of AVP onV2 receptors. In the rat model, chronic infusion of
desmopressin (DDAVP) caused an increase in proteinuria and AVP
suppression caused a decrease in proteinuria and improvement in
renal function (16).
AVP AND DIABETES
Vasopressin receptors are present in the liver and pancreas. V1a
receptors are found in hepatocytes and V1b receptors are found
in the cells of the islets of Langerhans in the pancreas. In liver,
AVP causes glycolysis thus elevating plasma glucose. Glucagon
also produces the same effect on the liver although it does not
act through V1a receptor. AVP can still produce this effect even
when the glucagon receptors are blocked since the receptors of
AVP and glucagon in the liver are different. V1b receptors are
present in both alpha and beta cells of the islets of Langerhans.
Thus, stimulation of islet cells causes stimulation of both insulin
and glucagon depending on extracellular glucose concentration.
Infusion of AVP causes a significant increase in plasma glucose
level in subjects with normal serum glucose. The effect of AVP on
glucose metabolism was demonstrated in animal experiments and
human trials. In an experiment with mice, the genes for V1a and
V1b receptors were knocked out. These mice had altered glucose
homeostasis and increased catabolism of fat suggesting that AVP
may play a role in metabolic disorders and glucose metabolism (3).
In addition, in human studies, it was found that people who
have a variant of AVPR1A (which encodes the V1a receptor), had
a higher fasting blood glucose level and an increased prevalence of
diabetes (17). Roussel et al. showed an inverse association between
water intake and the risk of hyperglycemia during a 9-year follow-
up. He compared the risk of developing diabetes in the future
based on current water intake. He noted that people who drank
more than 1 L of water had 27% less chance of getting diabetes
than people who drink less than 0.5 L/day. This observation was
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made after adjustment for confounding variables. This study pro-
poses that people who drink less water have a greater chance of
developing diabetes related to higher AVP levels (18).
Patients with Type I diabetes have selective depletion of beta
cells. They have impaired secretion of insulin but have intact secre-
tion of glucagon (alpha cells). Not only are the actions of insulin
and glucagon antagonistic, but secretion of insulin causes inhibi-
tion of the secretion of the glucagon. Therefore, in patients with
type 1 diabetes, secretion of glucagon is significantly increased as
there is no inhibition by insulin thus elevating the blood glucose
level. Therefore, in Type 1 diabetes, even physiological levels of
AVP can cause a profound increase in blood glucose by stimulat-
ing glucagon secretion resulting in increased production of glucose
by the liver (19).
To prove an association between AVP and glucose, Hsu et al.
conducted experiments with rats that were diabetic and non-
diabetic. Diabetes in rats was induced by the infusion of strep-
tozotocin. He initially measured basal secretion of glucagon in
both groups of rats before AVP was infused. He then infused AVP
and noted that the secretion of glucagon was double in the diabetic
rats compared to non-diabetic rats. Thus, the diabetic rat pancreas
was more sensitive to AVP in respect to glucagon secretion. They
also found that at baseline, before AVP was infused, diabetic rats
had a higher concentration of AVP in plasma than non-diabetic
rats. This study also showed that a lower concentration of AVP
is needed to increase glucagon secretion but a higher concentra-
tion of AVP was needed to secrete insulin. This suggests that alpha
cells are more sensitive to AVP than beta cells. AVP thus exerts
greater influence on glucagon secretion than insulin secretion at
basal levels. Since V1b receptors are involved in the stimulation
of glucagon, this study highlights that in the future, a V1b recep-
tor antagonist may play a role in the treatment of diabetes by
inhibiting unopposed glucagon secretion (19).
Also noteworthy, Dheen et al. has shown that in diabetic rats,
there is hypertrophy of the supraoptic and paraventricular nuclei
which suggests that there may be hyperactivity of neurons that
secrete AVP in diabetic rats (20). It has also been shown that the
concentration of AVP in the pancreas of humans and rats is much
higher than the concentration present in the serum. AVP is found
in the perivascular compartments of the pancreas and not in islet
or acinar cells. Thus, it is likely that locally formed pancreatic AVP
rather than pituitary AVP may play an important role in glucagon
production (3, 19).
Finally, Pasquali et al. showed that in obese male subjects when
CRH and AVP were infused, there was an exaggerated pituitary
response with an increased release of ACTH and a higher cortisol
level resulting in hyperglycemia. Thus, AVP has a role in causing
hyperglycemia by not only acting on islet cells but through its
action on V1b receptors in the pituitary (15). The various cells
and receptors that influence blood glucose levels are summarized
in Table 2.
AVP AND LIPIDS
Arginine vasopressin has been shown to control fat metabolism
by multiple mechanisms. Centrally, it stimulates the sympathetic
nervous system which in turn affects lipid metabolism (21).
Peripherally, AVP regulates lipid metabolism by regulation of
Table 2 | Cells, receptors, and the effects of arginine vasopressin on
blood glucose levels.
Hepatocytes V1a – glycolysis
Beta islet cells V1b – insulin release
Alpha islet cells V1b – glucagon release
CNS (pituitary) cells V1b – ACTH release increases glucocorticoids
Adrenal cortex V1a – increases glucocorticoids
several hormones affecting fat metabolism such as insulin,
glucagon, glucocorticoids, and epinephrine. AVP also inhibits tis-
sue lipase by its direct action on AVP receptors. AVP also affects
the glucose level, the substrate needed for fat metabolism (3).
Injection of AVP in the lateral ventricle of rat causes stimula-
tion of the sympathetic nervous system by a mechanism not well
understood. Sympathetic nervous system stimulation causes the
release of epinephrine which in turn causes stimulation of the
metabolism of TGs in adipose tissue. Peripheral nerve terminals
supply adipose tissue as well as the blood vessels of adipose tissue.
It has been shown by various studies that any interruption to these
nerve terminals to adipose tissue will affect lipid metabolism. In
human studies, infusion of epinephrine and norepinephrine lead
to elevation of free fatty acids (FFA) which are a byproduct of TG
metabolism (22).
Hiroyama et al. has shown in rat experiments that AVP has an
antilipolytic effect involvingV1a receptors. AVP exerts antilipolytic
action by inhibiting tissue lipase thus preventing the breakdown of
TG. In his experiment, he infused AVP in V1a-deficient rats and he
noted that these rats had increased lipolysis and increased serum
levels of glycerol and ketone bodies. AVP is also known to inhibit
the actions of isoproterenol. In V1a-deficient mice, isoproterenol
was infused and it was noted that in brown adipose tissue (BAT),
lipolysis was increased threefold (22). Stimulation of lipid metab-
olism in BAT is known to increase core temperature. Okuno et al.
in his experiments with rats has shown that AVP infusion caused
a decrease in the core body temperature due to inhibition of lipid
metabolism in the BAT. He noted that even in rats with an ante-
rior hypothalamic lesion, the infusion of AVP reduced core body
temperature. Thus, he concluded that this effect of AVP was not
centrally mediated but was peripheral due to the inhibition of fat
metabolism (23).
Insulin is the most potent antilipolytic hormone. Thus, insulin
therapy for diabetes causes obesity by inhibiting fat metabolism.
Insulin mediates this action by reducing the level of cyclic AMP
in cells. Insulin signaling is done through kinase Akt and p70S6
kinase. These kinases are activated by AVP such that AVP not
only causes stimulation of insulin release from islet of Langer-
hans but also enhances insulin signaling. In V1a-deficient rats,
insulin signaling is impaired which in turn causes insulin resis-
tance. Thus, V1a-deficient rats demonstrate increased lipolysis
secondary to insulin resistance. AVP can control lipid metab-
olism by controlling the glucose needed for lipid metabolism.
AVP stimulates glycogenolysis in the liver by stimulating glucagon
and epinephrine which in turn cause an increase in glucose
levels. Glucose is metabolized in the adipose tissue to TG. Insulin
facilitates this conversion (22).
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V1b receptors are present on the beta cells of the islets of
Langerhans. Fujiwara et al. in his experiments with V1b-deficient
mice showed that the serum level of insulin was reduced. This was
due to reduction of insulin release from the islets of Langerhans.
He also noted that these mice had increased insulin sensitivity
which probably acts as a compensatory response to low serum
insulin levels. Also, in these mice, lipolysis was impaired since V1b
receptor deficiency may stimulate lipogenesis by increasing insulin
sensitivity (24).
AVP AND HYPERTENSION
The interplay of the sympathetic nervous system, the renin
angiotensin aldosterone system (RAAS), and AVP relate to sys-
temic BP. It has been shown that on a day-to-day basis, AVP
does not play a significant role in the maintenance of BP (25).
Landry et al. in his human experiments, however, demonstrated
that vasopressin deficiency contributes to the vasodilatation of
septic shock (26).
Black people have a higher incidence of hypertension than
white people. The level of AVP has also been shown to be higher in
black individuals. Urine volume was lower in blacks compared
to whites and urine concentration was higher in black people
compared to whites especially in the daytime. Also, studies found
that even when BP was in the normal range, pulse pressure was
higher in black individuals. There was a strong statistical associa-
tion between higher urine concentration and high pulse pressure
in black men. Black men and women were compared with each
other regarding urine volume and urine concentrating ability and
it was shown that men had a higher ability to retain salt and con-
centrate urine than women. Increased conservation of sodium
caused less nocturnal dipping of BP in black men and increased
conservation of sodium in day time resulted in a higher BP at
night (27). Choukroun et al. showed that healthy subjects who
drank smaller amounts of water excreted sodium more slowly
compared to healthy subjects who drank a larger amount of water
(28). Bankir et al. made an association between urine flow rate and
urine sodium excretion in healthy subjects. The results showed that
urine sodium excretion was independent of urine flow rate as long
as urine flow was higher than 1 L but once urine flow was less than
1 L, sodium excretion decreased. This suggests that a higher level
of vasopressin is required for sodium conservation and sodium is
absorbed only when the AVP level reaches a certain threshold. A
higher vasopressin level in black people compared to whites could
be due to a change in the set point of the hypothalamic osmostat to
lower levels of serum osmolality. This higher AVP could be a sur-
vival advantage in black people for facilitating water conservation
in adverse drought and famine conditions. This adaptation could
cause decreased sodium excretion. In black people, RAAS activity
is low. This may explain why ACE inhibitors are not as effective in
black hypertensive patients (27).
It has also been shown in humans that acute stimulation of V2
receptors in men by DDAVP not only reduced urine volume but
that AVP causes an increase in the capacity of epithelial sodium
channel (ENaC) receptors in the distal nephron to absorb sodium.
This effect is solute-specific as the excretion of potassium and
creatinine did not change. The retention of sodium or impaired
sodium excretion can cause hypertension. Thus, hypertension in
black individuals is thought to be salt-sensitive as an increase in
salt intake will result in retention of sodium. AVP may also play
a significant role in salt-sensitive hypertension in chronic kidney
disease (CKD) patients due to a higher level of AVP causing activa-
tion of preglomerular V1a receptors and V2 receptors in collecting
tubule (29).
Further it has been demonstrated that AVP, at levels much
higher than needed to maintain an antidiuretic response, can cause
smooth muscle contraction by acting on V1a receptors. However,
this response is rapidly buffered by an intact autonomic nervous
system and intact cardiovascular reflexes causing activation of the
vagus nerve and bradycardia. It has been demonstrated in dogs
that if the autonomic nervous system is disrupted, acute infusion
of AVP will significantly elevate the mean arterial pressure (MAP).
Mohring et al. studied the effect of AVP on BP in normal subjects
and patients with idiopathic orthostatic hypotension presumably
secondary to autonomic dysfunction. The results revealed that to
increase MAP by 10 mm Hg, a 1000 times higher concentration
of AVP was needed in normal subjects than in those with auto-
matic insufficiency. These data suggest that a higher level of AVP
in primary hypertension in humans can have significant impact
on the cardiovascular system if the autonomic nervous system is
disrupted (30).
In summary, the complex interrelationships of AVP, sodium,
water, and other hormones in relation to the control of BP are of
great interest and should continue to be the object of study.
CHRONIC KIDNEY DISEASE PROGRESSION
Traditional risk factors for CKD progression such as diabetes,
hypertension, and albuminuria are well described. However,
numerous researchers have suggested that increased AVP levels can
cause worsening CKD. We know that water intake and vasopressin
levels are inversely related. Low 24 h urine volume and low water
intake has been correlated with worsening CKD and is known to be
associated with high AVP levels. Elevated urinary osmolality is not
only associated with worsening CKD but also associated with initi-
ation of dialysis after 72 months (31). In humans, the retrospective
MDRD trial has confirmed this association and this has been sup-
ported by experimental studies in rats. In these studies, continuous
infusion of DDAVP caused worsening albuminuria and CKD. On
the contrary, when V2 receptors were selectively blocked, the out-
come was opposite. Further, elevated copeptin levels, a surrogate
marker for AVP, are associated with albuminuria and decreasing
glomerular filtration rate (GFR) in kidney transplant patients (31).
Such observations support the hypothesis that V2 recep-
tor stimulation is associated with worsening CKD. Alcohol and
tobacco exert opposite influences on GFR. Alcohol blocks the
V2 receptor and tobacco stimulates the V2 receptor. Thus, alco-
hol can decrease the fall in GFR and tobacco increase the fall in
GFR (32, 33).
Arginine vasopressin may also cause worsening CKD by stimu-
lating the renin angiotensin system. AVP interacts with V2 recep-
tors causing direct stimulation of renin and indirectly it increases
renin activity by reducing sodium load to the macula densa. In
fact, DDAVP induced albuminuria and was associated with an
increase in renin activity and this action was blocked with an ACE
inhibitor. Increased RAAS activity causes constriction of efferent
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arteriole which causes hyperfiltration and glomerular damage with
worsening proteinuria (34).
Arginine vasopressin is also known to affect GFR. In ADPKD,
tolvaptan, a V2 receptor blocker, caused a significant slowing of
reduction of GFR. Anderson et al. in his human experiments
infused AVP in healthy volunteers for 2 h and he noted that
there was a significant increase in creatinine clearance which
was a reflection of higher GFR along with increased urine con-
centration and a decrease in fractional excretion of sodium
and urea (2). Hyperfiltration may induce glomerulosclerosis,
proteinuria, and worsening kidney disease. This effect may be
more relevant with high protein intake, male gender, and black
race (34).
In another study, a comparison was done between diabetic rats
that have normal vasopressin secretion and rats with no vaso-
pressin secretion. DM was generated by causing destruction of
islets of Langerhans cells by infusing streptozotocin. Over time,
rats that had diabetes and no vasopressin secretion had none of the
signs of early diabetic nephropathy compared to rats with diabetes
with intact vasopressin secretion. Also, urinary albumin excretion
(UAE) occurred to a much lesser extent in diabetic vasopressin-
deficient rats (35). Bardoux et al. has shown that in diabetic rats,
if tolvaptan is used and urine osmolality is reduced close to serum
osmolality, the rise of UAE was stopped (36). Desmopressin when
infused in healthy people not only increased urine osmolality but
also significantly increased UAE. In that study, urine creatinine did
not change (37).
The above data have been cited to support a role for AVP in the
progression of CKD.
AVP, KLOTHO, AND AGING
Arginine vasopressin may relate to the aging process through inter-
actions with the transmembrane protein klotho. Klotho is widely
expressed but it mainly influences the kidney and CNS. It also
has an extracellular domain and can be released into the blood
and the cerebrospinal fluid (CSF) and thus can also act as a hor-
mone. Klotho is a major determinant of life-span (38). Klotho
circulates in the blood and binds to receptors in various cells
and increases cellular resistance to oxidative stress thus extend-
ing life-span. Binding of klotho to its receptors also suppress the
intracellular insulin cascade also leading to increased resistance to
oxidative stress which contributes to the anti-aging properties of
klotho. Klotho-deficient rats have a decreased life-span, prema-
ture aging, and death occurs in less than 5 months. Apart from
these effects, klotho deficiency can also cause muscular dystrophy,
osteopenia, vascular calcification, and hearing loss which are other
accelerated age-related disorders (38).
Klotho inhibits the 1-alpha hydroxylase enzyme in the kidney
thus reducing the level of 1, 25 dihydroxycholecalciferol (1,25D) in
the blood. Klotho deficiency causes increased production of 1,25D
leading to hyperphosphatemia which in turn can increase vascular
calcification. Thus, the reduced life-span in klotho deficiency, at
least in part, can be explained by an increase in the 1,25D level.
In klotho-deficient mice, life span was significantly increased by a
low vitamin D diet (39).
Tang et al. studied the association between the klotho pro-
tein and dehydration. He conducted his study in hydrated and
36 h dehydrated mice. The study was also conducted in human
embryonic kidney cells. Klotho transcript level was measured by
polymerase chain reaction and protein abundance was detected by
western blot analysis. He found that klotho transcript and abun-
dance was significantly reduced in dehydrated mice. Dehydration
causes an increase in serum osmolarity, plasma AVP, aldosterone,
and 1,25D. Tang et al. exposed human embryonic kidney cells to a
high level of AVP and aldosterone and he noted that the expression
of klotho was significantly diminished by AVP and aldosterone;
thus AVP may have a role in reducing klotho expression. Elderly
diabetic patients are more prone to dehydration and may be at
increased risk for renal injury, accelerated aging and early death
possibly in association with secondary elevation of AVP levels and
their effect on klotho (40).
AVP AND SOCIAL BEHAVIOR
Vasopressin and oxytocin receptors are widely distributed in the
brain. V1a and V1b receptors are found in hippocampus, hypo-
thalamus, and cerebral cortex. V1b receptors are also found on
the pituitary and thus AVP may play a significant role in the
regulation of the hypothalamic–pituitary–adrenal axis (HPA) in
response to psychological stress. Oxytocin and AVP have a signifi-
cant effect on psychological and cognitive functions. Endogenous
AVP increases anxiety while endogenous oxytocin is anxiolytic.
Thus, both neuropeptides have different psychological responses
upon stimulation of their receptors and the balance of their actions
determines social and emotional responses. Dysregulated balance
between the actions of these peptides has been linked to vari-
ous mental disorders such as depression, anxiety, schizophrenia,
autism, personality disorders, and obsessive-compulsive disorders
(OCDs). In patients suffering with depression, both plasma levels
of AVP and levels of AVP in the paraventricular nucleus are sig-
nificantly increased. During anxiety and OCD, plasma and CSF
levels of AVP are significantly increased. Injection of hypertonic
saline has induced panic symptoms in patients susceptible to panic
attacks suggesting AVP may play a role in the induction of panic
symptoms (41).
During acute schizophrenia, the plasma level of AVP is elevated.
It has been suggested that the HPA response to psychological stress
is abnormal in patients with schizophrenia but normal in response
to physical stress. For example, CRH activates the HPA axis dur-
ing physical stress whereas AVP may activate the HPA axis during
psychological stress. This suggests that AVP may play a role in
pathophysiology of schizophrenia. This hypothesis is supported
by the actions of neuroleptic drugs like haloperidol which reduce
plasma AVP levels along with the control of psychiatric symptoms.
In contrast, phencyclidine (PCP) can induce severe symptoms
of schizophrenia by elevating plasma AVP levels and by altering
cerebral AVP receptor expression and distribution (42).
In autism, communication and reciprocal social interaction is
impaired. It has been shown in humans that intranasal AVP affects
social interaction. Further, autism has been linked to a mutation
in V1a receptor genes raising the possibility that AVP may play a
role in the impaired social behavior in autism (42).
Finally, intracerebral injection of AVP in animals has been
linked to aggressive behavior and increased anxiety. Over expres-
sion of V1a receptors is linked to increased anxiety. Mutant mice
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lacking V1a receptors were noted to have reduced anxiety and
impaired social recognition. Also, aggressive behavior in hamsters
was blocked with an oral V1A receptor antagonist. Microinjection
of a V1a receptor antagonist reduces anxiety in rats. Mouse null in
V1a and V1b receptors had impaired social interactions but had
normal motor functions which again suggests that AVP predom-
inantly affects psychological functions. V1a null mice were also
demonstrated to have reduced memory. In male rodents, AVP has
been linked to partner preference and paternal care after mating
and AVP antagonists altered this behavior (43).
AVP AND COGNITIVE FUNCTIONS
Since AVP may have the above actions on behavior, it has been
suggested that AVP may also have an effect on cognitive function.
Cognitive functions may be influenced by hydration status and
dehydration can increase AVP levels which may relate to changes
in mentation.
That severe dehydration can cause major organ dysfunction
and death is well known, but even mild dehydration and a loss of
1–2% of body weight can cause disturbances in cognitive func-
tion. Elderly diabetic patients and children are more prone to
dehydration and thus more likely to have behavioral issues due
to dehydration. Mild dehydration can occur during day-to-day
activity. Ganio et al. studied the impact of dehydration on cogni-
tive function and mood in an experiment conducted in 26 young
males. He noted that mild dehydration was associated with deteri-
oration in cognitive performance, visual vigilance, and an increase
in tension, anxiety, and fatigue. People who were hyperhydrated
had better memory functions than controls (44).
Spigt et al. studied the effect of dehydration on headache. He
conducted an experiment in migraine patients and randomized
them to receive placebo and 1.5 L of water daily. He noted that
there was not only reduction in intensity but also the reduction
in number of hours the patient suffered from headache in the
hydrated patients (45).
Although none of these experiments directly linked AVP to
changes in mood and cognitive function during dehydration,
serum osmolality increases even in mild dehydration which results
in an increase in AVP levels. It is therefore worthy of considera-
tion that elevated AVP with its many cerebral actions and effects
on behavior may also be related to the adverse cognitive effects of
dehydration (46).
AVP AND CELLULAR PROLIFERATION
Arginine vasopressin has been demonstrated to have an important
role in cell proliferation and growth by directly stimulating pro-
tein synthesis and the production of growth factors which in turn
cause cellular proliferation. AVP stimulates V1a receptors which
stimulate the intracellular enzyme cascade leading to cell cycle
progression and protein synthesis. The ability of AVP to induce cel-
lular proliferation and protein synthesis has been studied by using
radioactive thymidine. There was an increased uptake of radioac-
tive thymidine when cells were exposed to AVP. This increased
uptake was blocked by a V1a receptor antagonist but not by a V2
receptor antagonist (47).
Chiu et al. demonstrated the proliferative effect of AVP on
rat intestinal epithelial cells. Wear and tear of small intestinal
mucosa can cause a denuded area leading to cell migration from
the margin and increased cellular proliferation causing restitu-
tion of the intestinal epithelium. Chiu et al. exposed intestinal
epithelial cells to AVP without any other growth factors and
the authors noted both migration and cellular proliferation of
these cells in dose-dependent manner. This highlights the role
of AVP in the maintenance of small intestinal epithelium. AVP
is present in the crypt cells of the stomach and small intestine.
Thus, AVP through its paracrine effect is involved in the repair of
tissues (48).
Mesangial cells play a vital role in the microcirculation of the
glomerulus. Proliferation of glomerular cells can cause occlu-
sion of the capillaries. Many factors may cause proliferation of
the mesangial cells such as AVP, angiotensin-2, and endothelin-1,
which are present systemically and also produced locally. AVP is
known to cause proliferation of glomerular mesangial cells and
vascular smooth muscle cells by stimulating V1a receptors. In fact,
it has been shown that antagonists to V1a receptors given on a
chronic basis can inhibit mesangial cell proliferation (49). Another
mechanism by which AVP induces mesangial cellular proliferation
is by inducing autocrine secretion of vascular endothelial growth
factor (VEGF). AVP acts on V1a receptor which in turn causes
secretion of VEGF from mesangial cells. VEGF is a potent mito-
gen which in turn acts in an autocrine manner to cause mesangial
cell hypertrophy and proliferation. AVP also causes stimulation of
proliferation of fibroblasts present in the mesangium which cause
increased deposition of type 4 collagen leading to impairment of
glomerular microcirculation and injury (50).
Mackinnon et al. has shown that tumor cells of small cell
lung cancer (SCLC) demonstrate V1a receptors. SCLC cells secrete
neuropeptides and also have receptors for neuropeptides. In a
clinical trial conducted by Sethi et al., CD133 cancer cells from
SCLC patients resistant to the chemotherapeutic agent etoposide
were treated with a V1a receptor blocker called peptide 1 and it
was noted that these CD133 cancer cells which were resistant to
etoposide now became sensitive (51).
Arginine vasopressin also plays a major role in organ regener-
ation. In an animal experiment, partial hepatectomy was done in
rat liver. In this study, the plasma AVP level increased significantly
almost immediately and it peaked in 1 h by activation of the hypo-
thalamic nuclei. There was complete restoration of liver mass in a
few days suggesting that AVP has a significant role in liver regener-
ation. In another experiment, partial hepatectomy was also done
in rats. The action of AVP was blocked by using a V1a receptor
antagonist. V1a antagonism caused significantly decreased DNA
synthesis and decreased liver mass restoration in the first 24–48 h.
The significance of AVP in liver regeneration was also documented
in rats of the Brattleboro strain. These rats have hereditary AVP
deficiency. Partial hepatectomy was done in these rats and liver
generation was impaired and when AVP was administered liver
regeneration increased. This further demonstrates the significance
of AVP in hepatocyte regeneration (3).
The effect of AVP on protein synthesis was also demon-
strated in the neonatal mouse cardiomyocyte. Neonatal mouse
cardiomyocytes exposed to AVP for 24 h had increased protein syn-
thesis and an increase in the cell surface area in a dose-dependent
manner. This effect was lost in the presence of a V1a antagonist (3).
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The data summarized above suggest an important role for
AVP and AVP-blocking drugs in regard to cellular proliferation,
regeneration, and the growth of neoplasms.
AVP AND INFLAMMATION
Various inflammatory states such as pneumonia, encephalitis,
malaria, and adult respiratory distress syndrome are associated
with the development of inflammatory cytokines such as inter-
leukin 1 (IL-1) and interleukin 6 (IL-6) which have been shown to
be associated with the release of AVP (52). It has also been shown
that injection of IL-6 antibodies in the brain blocked the activation
of AVP-secreting neurons in response to injected lipopolysaccha-
ride (LPS). In humans, a temporal relationship was found between
injection of IL-6 and elevation of serum AVP levels. Serum AVP
levels were elevated within 2 h of IL-6 injection. This suggests that
IL-6 stimulates AVP-secreting neurons, increasing the serum levels
of AVP which may lead to the development of hyponatremia. The
mechanism of the release of AVP in response to the peripheral
injection of cytokines such as IL-6 is unclear. However, it is sug-
gested that IL-6 can diffuse across the BBB and it is also actively
secreted inside the brain BBB pericytes. Bacteremia in pediatric
patients is associated with an early rise of CRP levels. It has
been shown that elevated CRP is associated with hyponatremia.
Thus, hyponatremia could be used as a marker of inflammation
in certain settings (53).
Further, not only does the inflammatory response mediated
by cytokines stimulate the release of AVP, but it has been shown
that AVP has immunomodulatory actions. Boyd et al. in his ani-
mal experiments has shown that AVP can modulate the immune
response by downregulating innate immunity when exposed to
an antigen (54). LPS is a potent endotoxin and can stimulate
an innate immune response when given systemically. IL-6 is a
marker of innate immune response. Boyd et al. in his experi-
ments with rats, injected intraperitoneal LPS. LPS dramatically
increased the level of IL-6 in the serum and the lung compared
to controls that were given intraperitoneal saline. The IL-6 level
was monitored in the serum and the lung after low-dose AVP
injection. The investigators noted a significant reduction of IL-
6 in the lung after AVP exposure but no reduction of IL-6 in the
serum. This shows that the immunomodulatory action of AVP was
lung-specific. They also noted that the immunomodulatory action
of AVP was significantly suppressed when mice were pretreated
with a V2 receptor antagonist. This experiment demonstrates that
AVP reduces inflammation probably through V2 receptors in the
lungs. They also confirmed the immunomodulatory response of
AVP in human alveolar epithelial cells. Low-dose AVP injected
in mice did not affect hemodynamics but significantly reduced
the innate immune response. Thus, the efficacy of AVP in septic
shock may be due to both its vasoactive and immunomodulatory
properties (54).
Corticotropin-releasing hormone and AVP are not only present
in the cells within the hypothalamus but they are localized in
the cells of the immune system. AVP has been found in rat B
lymphocytes and thymic epithelial cells. AVP has also been found
in human peripheral blood mononuclear cells (PBMC). Human
PBMC have AVP receptors. Thus, in response to inflammation,
AVP can stimulate the production of cytokines and antibodies
through these receptors. AVP and CRH are released not only
from the hypothalamus but also from peripheral immune cells in
response to stress and inflammation (52). In rats, the expression of
AVP is increased in B cells during arthritis. In resting PBMC from
healthy humans, the concentration of CRH and AVP is low but it
is significantly increased in response to inflammation. In addition,
it has been shown in mice that blocking of V1a receptors in mice
altered the humoral immunity.
The HPA axis plays a significant role during inflammation.
Cytokines released during inflammation stimulate the release of
CRH and AVP from the hypothalamus. AVP and CRH act syn-
ergistically on the pituitary to release ACTH. ACTH stimulates
the adrenal cortex to release corticosteroid which in turn sup-
presses inflammation. Defective response of the hypothalamus to
inflammation leads to chronic inflammatory states due to dimin-
ished secretion of ACTH and corticosteroid. Lewis rats have a
defective neuroendocrine response to inflammation and this may
contribute to their chronic inflammatory state. HPA axis response
is diminished in patients with rheumatoid arthritis which is man-
ifested by a low cortisol level for the degree of joint inflammation.
AVP is also a pro-inflammatory peptide which can stimulate the
release of prolactin, a pro-inflammatory peptide, which can also
exacerbate inflammation. AVP stimulates the release of cytokines,
increases T helper 1 cell actions, and augments mixed lymphocytic
response further worsening inflammation. Immunoneutralization
of serum AVP in rats has been shown to diminish inflammation.
Thus, excessive production of AVP due to an abnormal HPA axis
may contribute to the chronic inflammatory state (55).
AVP AND INFECTIONS
Hormones including AVP play an important role in the manner in
which responses to infection are modulated. The upper and lower
urinary tract is generally considered a sterile environment and usu-
ally is not colonized by bacteria. Urinary tract infections are often
caused by uropathogenic Escherichia coli (UPEC) by retrograde
ascent of bacteria from the urinary bladder. UPEC has special
affinity to urinary bladder epithelium and renal tubular epithe-
lial cells (RTEC). Pyelonephritis can cause renal insufficiency in
children and adults and also can occur after renal transplantation.
The initial response of the body to any infection is in the form
of innate immunity. Innate immunity is considered as the first
line of defense and defends the host from infections in a non-
specific manner. Toll like receptors (TLRs) are pattern recognition
receptors. They identify pathogen-associated molecular pattern
(PAMP) resulting in activation of the innate immune response.
TLRs have a transmembrane domain and are present widely. They
are present on hematopoietic cells and different epithelial cell types
like intestinal cells and the RTEC of the collecting duct. RTEC play
a significant role in activating the innate immune response and
are the initial defense following the colonization of the kidney by
UPEC.
Lipopolysaccharide is an essential component of the cell wall
of Gram negative rods (GNRs). TLR4 present on the apical RTEC
recognizes the LPS and in turn activates a cascade of enzymatic
reactions which result in activation of nuclear transcription factors
(NF). NF in turn stimulates DNA to produce pro-inflammatory
cytokines. These cytokines activate the cells involved in innate
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immunity thus causing destruction of the GNR. Thus, TLRs are
essential in activating innate immunity, mounting host defense,
and preventing pyelonephritis (56).
Arginine vasopressin plays an important role in the reab-
sorption of water by increasing cyclic AMP levels. High cyclic
AMP levels cause reduction of the expression of the adhe-
sion and signaling molecules in the collecting duct cells after
bacterial translocation making innate immunity ineffective and
impairing renal bacterial clearance. DDAVP has been shown to
inhibit LPS-induced activation of NF thus inhibiting the release
of pro-inflammatory cytokines. V2 receptor antagonists prevent
the effects of DDAVP on inflammation thus causing increased
secretion of pro-inflammatory mediators and recruitment of neu-
trophils. This shows that AVP can play a role in interfering with
TR4-mediated signaling, downregulating intrarenal inflammation
and play a significant role in influencing innate immunity. Chil-
dren with pyelonephritis can exhibit high AVP levels. Experiments
in rats have shown that water deprivation significantly increases
the risk of pyelonephritis and sustained water diuresis can cure
enterococcal-induced pyelonephritis. Elderly patients are prone
to dehydration and this in part may explain the high incidence of
pyelonephritis in elderly patients. Hyperhydration decreases AVP
levels and thus may reinforce innate immunity, preventing and
limiting pyelonephritis. Thus, hormonal control of innate immu-
nity may to some degree explain susceptibility to pyelonephritis in
various individuals (57).
AVP AND HEMOSTASIS
Desmopressin, a synthetic derivative of vasopressin, was initially
used for the treatment of diabetes insipidus. Later, it was demon-
strated that DDAVP can also be used for the treatment of von
Willebrand’s disease and mild hemophilia as a transfusion saving
agent during major surgeries characterized by large blood loss. It
is also used in the treatment of bleeding due to platelet dysfunc-
tion from the use of aspirin, ticlopidine, uremia, or chronic liver
disease.
Desmopressin exerts its hemostatic effect by increasing the
serum levels of von Willebrand factor (vWF), factor VIII, and
tissue plasminogen activator (t-PA). vWF is a glycoprotein pro-
duced by endothelial cells, with a small contribution by platelets.
It exerts its hemostatic effect by binding platelets to the endothe-
lial cell and also by being a carrier protein for factor VIII reducing
its renal clearance and enzymatic degradation. t-PA and vWF are
produced by endothelial cells and are stored in secretory granules
called Weibel-palade (WP) bodies. DDAVP acts on endothelial
cells and stimulates the release of t-PA and vWF increasing serum
levels. The response to injected DDAVP is seen within 30 min
which suggests that the increase in the level of vWF and t-PA
is not due to increased production but is due to increased release
from WP bodies. This explains the tachyphylaxis to repeat doses
of DDAVP given at short intervals. It is suggested that factor VIII
is produced by endothelial cells and is localized in the WP bod-
ies along with vWF and t-PA and is released from the WP bodies
upon stimulation by DDAVP. The response to DDAVP is variable
among patients, thus a therapeutic trial should be given to esti-
mate individual responses prior to therapeutic use. The response
to intranasal DDAVP is much less and slower compared to DDAVP
given by the subcutaneous (SC) route or intravenously (IV). Thus,
during an emergency, the SC or IV route is preferred (58).
Desmopressin exerts its action through V2 receptors which are
present widely on the endothelial cell. DDAVP exerts its action
even in patients who have undergone bilateral nephrectomy sug-
gesting that extrarenal V2 receptors are involved in the release
of vWF. Further, a selective V2 receptor antagonist blocked the
response to DDAVP on endothelial cells. DDAVP also failed to
produce a response in patients with X-linked diabetes insipidus
in which there is a mutation of renal and extrarenal V2 recep-
tors. DDAVP causes an increase in cyclic AMP in the endothelial
cells which stimulates an enzymatic cascade releasing the factors
from the WP bodies. Further, DDAVP is unable to exert its action
on human umbilical vein epithelial cells (HUVECs) which lack V2
receptors confirming that DDAVP acts on endothelial cells through
V2 receptors (59).
AVP AND THE HYPOTHALAMIC–PITUITARY–ADRENAL AXIS
The HPA axis plays a vital role in the maintenance of homeostasis
in response to stress. The HPA axis reacts to stress by releas-
ing ACTH which acts on the adrenal cortex to release corticos-
teroids. Corticosteroid influences multiple physiological functions
in response to stress. Dysfunction of the HPA axis can result in a
chronic inflammatory state due to the deficiency of corticosteroids.
CRH mainly influences the release of ACTH, however, AVP also
plays a significant role in releasing ACTH in response to stress by
directly acting on V1b receptors in the pituitary and AVP also acts
synergistically by potentiating the actions of CRH. Intraperitoneal
or oral administration of a V1b receptor antagonist prevents the
increase in the ACTH level in response to injected AVP. Moreover,
in mice lacking V1b receptors, the ACTH level was not increased in
response to injected AVP. In mice, the increase in the ACTH level
was also prevented by a V1b receptor blocker in response to stress
such as acute restraint and LPS injection. This demonstrates that
CRH can not compensate for the V1b receptor blockade suggesting
an important role of AVP in increasing ACTH levels in response to
acute stress. It has also been suggested that AVP does not play an
important role in the resting hormone level of ACTH and corticos-
teroid. This was shown in Brattleboro rats which congenitally lack
AVP. In these rats, basal level of ACTH and corticosteroid did not
differ compared to controls. However, the stress-induced ACTH
level was markedly impaired in these Brattleboro rats compared to
controls. In has also been stated that in response to chronic stress
such as repeated restraints, ACTH level is increased mainly by AVP
rather than CRH (3).
Apart from its action of releasing ACTH,AVP plays a significant
role in regulating the release of the hormones of the adrenal gland
by acting on V1a and V1b receptors. V1a receptors are located in
the adrenal cortex and V1b receptors are located on the chromaffin
cells in the adrenal medulla. AVP is not only produced centrally but
it is also produced locally in many tissues and this has been demon-
strated in the adrenal medulla by the presence of the immunore-
activity of AVP along with epinephrine and norepinephrine in the
chromaffin cells in the adrenal medulla. It has been suggested that
AVP is produced and secreted by chromaffin cells in response to
acetylcholine and stress. AVP acts on V1b receptors on the chro-
maffin cells secreting epinephrine and norepinephrine in response
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to acute and chronic stress acting in an autocrine and paracrine
manner. The significance of V1b receptors was demonstrated in
mice lackingV1b receptors. Basal levels of epinephrine and norepi-
nephrine were similar in V1b-deficient mice compared to controls.
However, in response to acute and chronic stress, the levels of
epinephrine and norepinephrine were significantly less (60).
Arginine vasopressin also acts on V1a receptors in the adrenal
cortex and stimulates hypertrophy and hyperplasia of the cells in
the adrenal cortex thus resulting in the enlargement of the zona
glomerulosa. This results in increased production and secretion
of aldosterone and corticosteroid. This response was blocked by
a V1a receptor antagonist and in mice which lack V1a recep-
tors. Brattleboro rats, which are deficient in vasopressin, have
diminished secretion of aldosterone suggesting that AVP stim-
ulates aldosterone secretion directly independent of its action on
ACTH secretion (61). It has also been suggested that AVP may play
an important role in the pathophysiology of Cushing’s syndrome.
Cushing’s syndrome can be caused by an adrenal tumor or hyper-
plasia which is ACTH-independent. It has been demonstrated that
these tumor cells have either over expressed V1a receptors or have
a mutated form of V1a receptor leading to increased sensitivity to
AVP causing increased secretion of corticosteroid (62).
Thus, AVP plays an important role in regulating the HPA by
centrally releasing AVP and also the peripheral production of
AVP influences secretion of hormones of the adrenal gland by
its autocrine and paracrine functions.
CONCLUSION
The above comprehensive review describes the various nonpressor
and nonantidiuretic actions of AVP. Appreciation of these relation-
ships should stimulate further research activities in these areas of
great potential importance.
REFERENCES
1. Robertson GL. The regulation of vasopressin functions in health and disease.
Recent Prog Horm Res (1975) 33:333–85.
2. Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P. Antidiuretic effect of
subnormal levels of arginine vasopressin in normal humans. Am J Physiol (1990)
259(1 Pt 2):R53–60.
3. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue
A. Vasopressin V1a and V1b receptors: from molecules to physiological systems.
Physiol Rev (2012) 92(4):1813–64. doi:10.1152/physrev.00035.2011
4. Luttinger D, Hernandez DE, Nemeroff CB, Prange AJ Jr. Peptides and nocicep-
tion. Int Rev Neurobiol (1984) 25:185–241. doi:10.1016/S0074-7742(08)60680-7
5. Bodnar RJ, Wallace MM, Kordower JH, Nilaver G, Cort J, Zimmerman EA.
Modulation of nociceptive thresholds by vasopressin in the Brattleboro and
normal rat. Ann N Y Acad Sci (1982) 394(1):735–9. doi:10.1111/j.1749-6632.
1982.tb37491.x
6. Ahn DK, Kim KH, Ju JS, Kwon S, Park JS. Microinjection of arginine vasopressin
into the central nucleus of amygdala suppressed nociceptive jaw opening reflex
in freely moving rats. Brain Res Bull (2001) 55(1):117–21. doi:10.1016/S0361-
9230(01)00493-2
7. Watkins LR, Suberg SN, Thurston CL, Culhane ES. Role of spinal cord neuropep-
tides in pain sensitivity and analgesia: thyrotropin releasing hormone and vaso-
pressin. Brain Res (1986) 362(2):308–17. doi:10.1016/0006-8993(86)90455-5
8. Yang J, Lu L, Wang HC, Zhan HQ, Hai GF, Pan YJ, et al. Effect of intranasal
arginine vasopressin on human headache. Peptides (2012) 38(1):100–4. doi:10.
1016/j.peptides.2012.07.029
9. Tamma R, Sun L, Cuscito C, Lu P, Corcelli M, Li J, et al. Regulation of bone
remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl
Acad Sci U S A (2013) 110(46):18644–9. doi:10.1073/pnas.1318257110
10. Sejling A, Pedersen-Bjergaard U, Eiken P. Syndrome of inappropriate ADH secre-
tion and severe osteoporosis. J Clin Endocrinol Metab (2012) 97(12):4306–10.
doi:10.1210/jc.2012-2031
11. Barsony J, Sugimura Y, Verbalis JG. Osteoclast response to low extracellular
sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem
(2011) 286(12):10864–75. doi:10.1074/jbc.M110.155002
12. Hew-Butler T, Stuempfle KJ, Hoffman MD. Bone: an acute buffer of plasma
sodium during exhaustive exercise? Horm Metab Res (2013) 45(10):697–700.
doi:10.1055/s-0033-1347263
13. Sandhu HS, Gilles E, DeVIta MV, Panagopoulos G, Michelis MF. Hyponatremia
associated with large-bone fracture in elderly patients. Int Urol Nephrol (2009)
41(3):733–7. doi:10.1007/s11255-009-9585-2
14. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH
Jr, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker
of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab (2009)
94(7):2558–64. doi:10.1210/jc.2008-2278
15. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, et al.
ACTH and cortisol response to combined corticotropin releasing hormone-
arginine vasopressin stimulation in obese males and its relationship to body
weight, fat distribution and parameters of the metabolic syndrome. Int J Obes
Relat Metab Disord (1999) 23(4):419–24. doi:10.1038/sj.ijo.0800838
16. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G,
et al. Plasma copeptin and the risk of diabetes mellitus. Circulation (2010)
121(19):2102–8. doi:10.1161/CIRCULATIONAHA.109.909663
17. Enhörning S, Leosdottir M, Wallström P, Gullberg B, Berglund G, Wirfält E, et al.
Relation between human vasopressin 1a gene variance, fat intake, and diabetes.
Am J Clin Nutr (2009) 89(1):400–6. doi:10.3945/ajcn.2008.26382
18. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, et al.
Low water intake and risk for new-onset hyperglycemia. Diabetes Care (2011)
34(12):2551–4. doi:10.2337/dc11-0652
19. Yibchok-anun S, Abu-Basha EA,Yao CY, Panichkriangkrai W, Hsu WH. The role
of arginine vasopressin in diabetes-associated increase in glucagon secretion.
Regul Pept (2004) 122(3):157–62. doi:10.1016/j.regpep.2004.06.010
20. Dheen ST, Tay SS, Wong WC. Arginine vasopressin and oxytocin-likes
immunoreactive neurons in the hypothalamic paraventricular and supraop-
tic nuclei of streptozotocin-induced diabetic rats. Arch Histol Cytol (1994)
57(5):461–72. doi:10.1679/aohc.57.461
21. Havel RJ, Goldfien A. The role of the sympathetic nervous system in the metab-
olism of free fatty acids. J Lipid Res (1959) 1(1):102–8.
22. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K,
et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol
Endocrinol (2007) 21(1):247–58. doi:10.1210/me.2006-0069
23. Okuno A, Yamamato M, Itoh S. Lowering of the body temperature induced by
vasopressin. Jpn J Physiol (1965) 15(4):378–87. doi:10.2170/jjphysiol.15.378
24. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi JI, Yamauchi J, et al.
Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol
(2007) 584(1):235–44. doi:10.1113/jphysiol.2007.136481
25. Gavras H, Hatzinikolaou P, North W, Bresnahan M, Gavras I. Interaction of the
sympathetic nervous system with vasopressin and renin in the maintenance of
blood pressure. Hypertension (1982) 4(3):400–5. doi:10.1161/01.HYP.4.3.400
26. Landry DW, Levin HR, Gallant EM, Ashton RC, Seo S, D’Alessandro D, et al.
Vasopressin deficiency contributes to the vasodilation of septic shock. Circula-
tion (1997) 95(5):1122–5. doi:10.1161/01.CIR.95.5.1122
27. Bankir L, Perucca J, Weinberger MH. Ethnic differences in urine concentra-
tion: possible relationship to blood pressure. Clin J Am Soc Nephrol (2007)
2(2):304–12. doi:10.2215/CJN.03401006
28. Choukroun G, Schmitt F, Martinez F, Drüeke TB, Bankir L. Low urine flow
reduces the capacity to excrete a sodium load in humans. Am J Physiol (1997)
273(5):R1726–33.
29. Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N. Chronic expo-
sure to vasopressin upregulates ENaC and sodium transport in the rat renal col-
lecting duct and lung. Hypertension (2001) 38(5):1143–9. doi:10.1161/hy1001.
092641
30. Möhring J, Glänzer K, Maciel JA Jr, Däsing R, Kramer HJ, Arbogast R, et al.
Greatly enhanced pressor response to antidiuretic hormone in patients with
impaired cardiovascular reflexes due to idiopathic orthostatic hypotension.
J Cardiovasc Pharmacol (1980) 2(4):367–76. doi:10.1097/00005344-198007000-
00004

























































Mavani et al. Nonpressor and nonantidiuretic actions of the hormone vasopressin
31. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention
and retardation of kidney disease? Nat Rev Nephrol (2013) 9(4):223–39.
doi:10.1038/nrneph.2013.22
32. Stack AG, Murthy BV. Cigarette use and cardiovascular risk in chronic kidney
disease: an unappreciated modifiable lifestyle risk factor. Semin Dial (2010)
23(3):298–305. doi:10.1111/j.1525-139X.2010.00728.x
33. Schaeffner E, Ritz E. Alcohol and kidney damage: a Janus-faced relationship.
Kidney Int (2012) 81(9):816–8. doi:10.1038/ki.2012.14
34. Torres VE. Vasopressin in chronic kidney disease: an elephant in the room?
Kidney Int (2009) 76(9):925–8. doi:10.1038/ki.2009.325
35. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM,
et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hyper-
trophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc
Natl Acad Sci U S A (1999) (18):10397–402. doi:10.1073/pnas.96.18.10397
36. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albu-
minuria: role of antidiuretic hormone as revealed by chronic V2 receptor antag-
onism in rats. Nephrol Dial Transplant (2003) 18(9):1755–63. doi:10.1093/ndt/
gfg277
37. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, et al. Vaso-
pressin increases urinary albumin excretion in rats and humans: involvement of
V2 receptors and the renin–angiotensin system. Nephrol Dial Transplant (2003)
18(3):497–506. doi:10.1093/ndt/18.3.497
38. Kuro-o M. Klotho. Pflügers Arch (2010) 459(2):333–43. doi:10.1007/s00424-
009-0722-7
39. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity
accelerating mammalian aging. FASEB J (2010) 24(9):3562–71. doi:10.1096/fj.
09-152488
40. Tang C, Pathare G, Michael D, Fajol A, Eichenmüller M, Lang F. Downregu-
lation of klotho expression by dehydration. Am J Physiol Renal Physiol (2011)
301(4):F745–50. doi:10.1152/ajprenal.00037.2011
41. Egashira N, Mishima K, Iwasaki K, Oishi R, Fujiwara M. New topics in vaso-
pressin receptors and approach to novel drugs: role of the vasopressin receptor
in psychological and cognitive functions. J Pharmacol Sci (2009) 109(1):44–9.
doi:10.1254/jphs.08R14FM
42. Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social
behavior. Front Neuroendocrinol (2009) 30(4):548–57. doi:10.1016/j.yfrne.2009.
05.005
43. Keverne EB, Curley JP. Vasopressin, oxytocin and social behaviour. Curr Opin
Neurobiol (2004) 14(6):777–83. doi:10.1016/j.conb.2004.10.006
44. Ganio MS, Armstrong LE, Casa DJ, McDermott BP, Lee EC,Yamamoto LM, et al.
Mild dehydration impairs cognitive performance and mood of men. Br J Nutr
(2011) 106(10):1535–43. doi:10.1017/S0007114511002005
45. Spigt MG, Kuijper EC, Schayck CP, Troost J, Knipschild PG, Linssen VM, et al.
Increasing the daily water intake for the prophylactic treatment of headache:
a pilot trial. Eur J Neurol (2005) 12(9):715–8. doi:10.1111/j.1468-1331.2005.
01081.x
46. Wilson MG, Morley JE. Impaired cognitive function and mental performance in
mild dehydration. Eur J Clin Nutr (2003) 57:S24–9. doi:10.1038/sj.ejcn.1601898
47. Thibonnier M, Plesnicher CL, Berrada K, Berti-Mattera L. Role of the human V1
vasopressin receptor COOH terminus in internalization and mitogenic signal
transduction. Am J Physiol Endocrinol Metab (2001) 281(1):E81–92.
48. Chiu T, Wu SS, Santiskulvong C, Tangkijvanich P, Yee HF Jr, Rozengurt E.
Vasopressin-mediated mitogenic signaling in intestinal epithelial cells. Am J
Physiol Cell Physiol (2002) 282(3):C434–50. doi:10.1152/ajpcell.00240.2001
49. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. Arginine vasopressin stim-
ulates mesangial cell proliferation by activating the epidermal growth factor
receptor. Am J Physiol Renal Physiol (2001) (6):F972–9.
50. Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M. Vasopressin increases
type IV collagen production through the induction of transforming growth
factor-beta secretion in rat mesangial cells. Pharmacol Res (2008) 57(2):142–50.
doi:10.1016/j.phrs.2008.01.003
51. MacKinnon AC, Tufail-Hanif U, Wheatley M, Rossi AG, Haslett C, Seckl M,
et al. Targeting V1A-vasopressin receptors with [Arg6, D-Trp7, 9, NmePhe8]-
substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.
Br J Pharmacol (2009) 156(1):36–47. doi:10.1111/j.1476-5381.2008.00003.x
52. Baker C, Richards LJ, Dayan CM, Jessop DS. Corticotropin-releasing hor-
mone immunoreactivity in human T and B cells and macrophages: colocal-
ization with arginine vasopressin. J Neuroendocrinol (2003) 15(11):1070–4.
doi:10.1046/j.1365-2826.2003.01099.x
53. Park SJ, Shin JI. Inflammation and hyponatremia: an underrecognized condi-
tion? Korean J Pediatr (2013) 56(12):519–22. doi:10.3345/kjp.2013.56.12.519
54. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR. Vasopressin decreases
sepsis-induced pulmonary inflammation through the V2R. Resuscitation (2008)
79(2):325–31. doi:10.1016/j.resuscitation.2008.07.006
55. Chikanza IC, Grossman AS. Hypothalamic-pituitary-mediated immunomodu-
lation: arginine vasopressin is a neuroendocrine immune mediator. Rheumatol-
ogy (1998) 37(2):131–6. doi:10.1093/rheumatology/37.2.131
56. Chassin C, Tourneur E, Bens M, Vandewalle A. A role for collecting duct epithe-
lial cells in renal antibacterial defences. Cell Microbiol (2011) 13(8):1107–13.
doi:10.1111/j.1462-5822.2011.01614.x
57. Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM,Vimont S, et al. Hormonal
control of the renal immune response and antibacterial host defense by arginine
vasopressin. J Exp Med (2007) 204(12):2837–52. doi:10.1084/jem.20071032
58. Franchini M. The use of desmopressin as a hemostatic agent: a concise review.
Am J Hematol (2007) 82(8):731–5. doi:10.1002/ajh.20940
59. Kaufmann JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer
UM. Vasopressin-induced von Willebrand factor secretion from endothelial
cells involves V2 receptors and cAMP. J Clin Invest (2000) 106(1):107–16.
doi:10.1172/JCI9516
60. Guillon G, Grazzini E, Andrez M, Breton C, Trueba M, Gal CSL, et al. Vaso-
pressin: a potent autocrine/paracrine regulator of mammal adrenal functions.
Endocr Res (1998) 24(3–4):703–10. doi:10.3109/07435809809032672
61. Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin.
Horm Metab Res (1998) 30(06/07):360–7. doi:10.1055/s-2007-978899
62. Horiba N, Suda T, Aiba M, Naruse M, Nomura K, Imamura M, et al. Lysine vaso-
pressin stimulation of cortisol secretion in patients with adrenocorticotropin-
independent macronodular adrenal hyperplasia. J Clin Endocrinol Metab (1995)
80(8):2336–41. doi:10.1210/jc.80.8.2336
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 January 2015; accepted: 09 March 2015; published online: 24 March 2015.
Citation: Mavani GP, DeVita MV and Michelis MF (2015) A review of the nonpres-
sor and nonantidiuretic actions of the hormone vasopressin. Front. Med. 2:19. doi:
10.3389/fmed.2015.00019
This article was submitted to Nephrology, a section of the journal Frontiers in Medicine.
Copyright © 2015 Mavani, DeVita and Michelis. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org March 2015 | Volume 2 | Article 19 | 11
